

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EU524615943US Express Mail Label Number	April 15, 2005 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
MARGARET FORNEY PRESCOTT
INTERNATIONAL APPLICATION NO: PCT/EP03/11379
FILED: 14 OCTOBER 2003
U.S. APPLICATION NO: Not Yet Assigned
35 USC §371 DATE:
FOR: BISPHOSPHONATES FOR THE TREATMENT OF ATHEROSCLEROSIS
AND DEVICES COMPRISING THEM

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/11379, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7960
Date: April 15, 2005

Respectfully submitted,


Edward J. Wilusz, Jr.
Attorney for Applicant
Reg. No. 52,370

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PA/4-32723A
APPLICATION NO.
Not Yet Assigned
APPLICANT
MARGARET FORNEY PRESCOTT
FILING DATE

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	YLITALO RITVA ET AL: "Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate" Pharmacology And Toxicology, vol. 90, no. 3, March 2002 (2002-03), pages 139-143
	DB	JAGDEV S P ET AL: "The Bisphosphonate, Zoledronic Acid, Induces Apoptosis Of Breast Cancer Cells: Evidence For Synergy With Paclitaxel" British Journal Of Cancer, London, GB, vol. 8, no. 84, 2001, pages 1126-1134
	DC	LEVY R J ET AL: "Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis" Journal Of Controlled Release, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 36, no. 1, 1 September 1995, pages 137-147
	DD	BURNETT ET AL.: "cardiovascular disease and osteoporosis: is there a link between lipids and bone" Annals Of Clinical Biochemistry, vol. 39, April 2002 (2002-04), pages 203-210
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. D. 10/531677
PA/4-32723A
APPLICATION NO.
Not Yet Assigned
APPLICANT
MARGARET FORNEY PRESCOTT
FILING DATE

Sheet 1 of 1

Rec'd PCT/PTO 15 APR 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 00 03677	1/27/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01 49295	7/12/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	YLITALO: "Bisphosphonates and atherosclerosis" GENERAL PHARMACOLOGY, vol. 35, 2002, pages 287-296
	AS	PRICE ET AL.: "bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption" Arteriosclerosis, Thrombosis And Vascular Biology, vol. 21, no. 5, 2001
	AT	KOSHIYAMA HIROYUKI ET AL: "Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes" Journal Of Clinical Endocrinology And Metabolism, vol. 85, no. 8, August 2000

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.